Biocytogen is dedicated to the discovery and development of novel antibody-based drugs to meet unmet medical needs, with a particular focus on oncology, autoimmune, inflammatory, metabolic, and other diseases. The company’s current assets include monoclonal antibodies, bispecific antibodies, bispecific ADCs, etc. By advancing its R&D capabilities and establishing key partnerships for licensing and co-development opportunities, Biocytogen aims to deliver transformative therapies to patients in need.
To learn more about our assets, or to explore licensing/co-development opportunities. please contact [email protected].
Candidate |
Target |
Combination |
Indication |
Phase |
Upcoming Milestone |
Rights |
News/Press Release |
|
Clinical-stage Drug Candidates |
YH003 |
CD40 |
PD-1 | Melanoma | Global MRCT
Phase II |
2022 Q4 Complete Recruitment | Global | Biocytogen/Eucure Biopharma Announce First Patient Dosed in Phase II Clinical Trial of YH003 Combination Therapy as a First-Line Treatment for Mucosal Melanoma |
| PD-1 | Pancreatic cancer |
Global MRCT
Phase II |
2022 Q4 Complete Recruitment | |||||
| Monotherapy |
Solid tumors | China Phase I | 2022 Q2 Patient Recruitment |
|||||
| PD-1+ YH001 |
Solid tumors | Australia
IND |
2023 Q1 Complete Recruitment | |||||
| PD-1 | Mucosal melanoma | China | 2022 Q3 Complete Recruitment | |||||
| YH001 |
CTLA-4 |
PD-1 | Non-small-cell lung cancer (NSCLC) |
Global MRCT
Phase II |
2023 Q1 Patient Recruitment |
Global |
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting |
|
| PD-1 | Hepatocellular carcinoma (HCC) |
Global MRCT
Phase II
|
2023 Q1 Patient Recruitment |
|||||
| Monotherapy | Solid tumors | China
Phase I |
2022 Q2 Complete Site Visit | |||||
| PD-L1 | Sarcoma | Global MRCT | 2022 Q3 Patient Recruitment |
|||||
| YH002 |
OX40 |
Monotherapy | Solid Tumors | Australia
Phase 1 |
2022 Q3 Complete Phase I trial |
Global | First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia | |
| Monotherapy | Solid Tumors | China/USA
Phase 1 |
Launch based on clinical results in Australia |
|||||
| YH001 | Solid Tumors | China/Australia
Phase I |
2023 Q1 Complete Recruitment | |||||
| YH004 |
4-1BB |
PD-1 | Hematological malignancies |
Australia
Phase 1 |
2023 Q4 Complete Recruitment | Global | ||
| PD-1 | Solid tumors | Australia/China
Phase 1
|
2023 Q4 Complete Recruitment | |||||
| YH005-ADC | Claudin18.2- ADC |
Solid tumors | Australia
IND -> Phase 1 |
Remegen | ||||
| Developmental -stage Drug Candidates |
YH008 | PD-1/CD40 (bispecific antibody) |
Solid tumors | CMC | Global | |||
| YH006 | CTLA-4/ OX40 (bispecific antibody) |
Solid Tumors | CMC | Global | ||||
| YH009 | RSV | Prevention/ Treatment for RSV infection |
CMC | Global | ||||
| YH010 | PD-L1/IL-12 | Solid Tumors | Discovery | Global | ||||
| YH011 | PD-L1/ cytokine |
Solid Tumors | Discovery | GeneQuantum Healthcare | ||||
| YH012 | Bispecific antibody ADC |
Solid tumors | Discovery | Global | ||||
| YH013 | Bispecific antibody ADC |
Solid tumors | Discovery | Global |
